March 24th 2023
No significant budget increase was observed in patients with non-radiographic axial spondyloarthritis (nr-axSpA) receiving secukinumab.
March 23rd 2023
FDA Approves High-Concentration Formulation Biosimilar Adalimumab-AdazMarch 21st 2023
The approval was based on positive results from the phase I pharmacokinetics bridging study, which showed comparable PK and similar safety and immunogenicity of adalimumab 50 mg/mL and adalimumab high-concentration formulation.
Exposure to Rituximab Biosimilars did not Increase Hypersensitivity Reaction HospitalizationsMarch 14th 2023
A recent study found no association between exposure to rituximab biosimilars and hospitalization for hypersensitivity reactions compared to the biologic at initiation, at switch, or over time.
Etanercept Biosimilars Outperform Biologic in ACR50 Response Rate at 1 YearMarch 9th 2023
Although etanercept biosimilars demonstrated comparable efficacy, safety, and immunogenicity when compared with the reference drug, biosimilar treatment was associated with a better ACR50 response rate.
An Increase in Infliximab Biosimilar Dose Escalation Results in Improved IBD Health OutcomesMarch 8th 2023
There was a 0.9% increase in the first dispensation of infliximab, either the biosimilar or originator during the first year of follow-up, as well as a 16.2% increase in infliximab dose escalation, a 2.4% decrease in the dispensation of antibiotics, and a 2.6% decrease in the new use of prednisone.
Tocilizumab Biosimilar, MSB11456, Demonstrates Similar Pharmacokinetics, Safety ProfilesFebruary 24th 2023
A recent study found that the biosimilar MSB11456 showed pharmacokinetic similarity, immunogenicity, and safety profiles comparable to the reference drug, tocilizumab, suggesting that it could be a cost-effective alternative for treating autoimmune disorders.
Mandatory Switching Policies More Effectively Increase Uptake of BiosimilarsFebruary 14th 2023
Pharmaceutical claims data were collected for the reference drugs and etanercept and infliximab biosimilars to analyze changes in the proportions of dispensed of and total spending on biosimilars after the new start and biosimilar switching policies began.
Infliximab Biosimilar Competition did not Improve Affordability for PatientsFebruary 1st 2023
Investigators evaluated whether the availability of the biosimilar infliximab was linked to lower out-of-pocket costs using claims from the IBM MarketScan national data set of commercially insured patients.
Study Highlights Need For Policies To Seek Utilization, Support Sustainable Market Of BiosimilarsJanuary 24th 2023
Shifts towards on-patient and higher-cost therapies have been observed in TNF-alpha inhibitor biosimilar availability. Therefore, the importance of investing in biosimilars is encouraged.
No Safety, Efficacy Differences Observed in Patients Switched to Adalimumab Biosimilar from OriginatorJanuary 22nd 2023
The safety and efficacy of 4 adalimumab biosimilars was compared in a real-life setting in adult patients with IBD switching from the originator for a non-medical reason.
Infliximab Biosimilar Shows Promise for Multiple Conditions in Phase 4, Post-Marketing Trial in KoreaJanuary 20th 2023
A phase 4, post-marketing surveillance study in Korea provides insight into the safety and efficacy of SB2, an infliximab biosimilar, across a wide range of immune-mediated inflammatory diseases, including rheumatoid arthritis, ulcerative colitis, and ankylosing spondylitis.